The laboratory, which was set up in September last year to provide earl-stage analysis services, was deemed to meet all of the CAP’s criteria for data that can accelerate drug development and improve patient safety.
The unit is the fourth facility owned by the US contract research organisation (CRO) to have been approved by the CAP.
Steve Lobel, vice president of PPD's global central laboratory operations, said that: “Achieving CAP accreditation six weeks after opening our Singapore facility demonstrates the expertise of our scientists and our commitment to excellence."
